As a result, ramucirumab prevents the binding of VEGF-C and VEGF-D to VEGFR-2, thereby inhibiting their activity and contributing to anti-angiogenic effects in the treatment of cancers, including CRC. The gene discussed is KDR; the disease is cancer.